What's new in antiplatelet and anticoagulant therapy recommendations for unstable angina/non-ST-elevation myocardial infarction: 2012 focused update from the American College of Cardiology Foundation/American Heart Association task force on practice guidelines.
This focused update addresses the use of the newly approved oral antiplatelet agents, prasugrel and ticagrelor, for the management of patients with UA/NSTEMI.
Division of Cardiology, Emory University School of Medicine, Atlanta, GA 30303, USA. nwenger@emory.edu
Nanette K
NK
Wenger
D000241:Adenosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000284:Administration, Oral; D000789:Angina, Unstable / Q000188:drug therapy*; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D018570:Risk Assessment; D012307:Risk Factors; D013876:Thiophenes / Q000627:therapeutic use; D000077486:Ticagrelor; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D014859:Warfarin; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine